Astrocyte-elevated gene-1 confers resistance to pemetrexed in non-small cell lung cancer by upregulating thymidylate synthase expression

Previous studies have suggested that astrocyte-elevated gene-1 (AEG-1) contributes to the mechanisms of resistance to various chemotherapeutics. In this study, we investigated whether AEG-1 expression level correlated with that of thymidylate synthase (TS), as higher TS expression is known to be associated with the resistance to pemetrexed chemotherapy in patients with advanced lung adenocarcinoma. Using pemetrexed-resistant lung adenocarcinoma PC-9 cell line, we demonstrated that transfection of AEG-1 siRNA lowered TS expression and decreased pemetrexed IC50 value. In contrast, overexpression of AEG-1 was associated with increased expression of TS and higher pemetrexed IC50 value. Immunohistochemical staining of clinical biopsy samples showed that patients with lower AEG-1 expression had longer overall survival time. Moreover, analysis of repeated biopsy samples revealed that an increase in the TS level from baseline to disease progression was significantly associated with the elevation of AEG-1 expression. In conclusion, our data demonstrated that TS expression might be regulated by AEG-1 and that increased expression of these proteins contributes to lung cancer disease progression and may be associated with the development of resistance to pemetrexed.

[1]  B. Jiang,et al.  B7-H3 increases thymidylate synthase expression via the PI3k-Akt pathway , 2016, Tumor Biology.

[2]  Sandra Zazo,et al.  Thymidylate synthase expression as a predictive biomarker of pemetrexed sensitivity in advanced non-small cell lung cancer , 2015, BMC Pulmonary Medicine.

[3]  Shan Lu,et al.  The expression of astrocyte elevated gene‐1 in human non‐small‐cell lung cancer and its relationship with postoperative chemotherapy and radiotherapy , 2015, Histopathology.

[4]  Hui Zhang,et al.  RNA Interference-Mediated Knockdown of Astrocyte Elevated Gene-1 Inhibits Growth, Induces Apoptosis, and Increases the Chemosensitivity to 5-Fluorouracil in Renal Cancer Caki-1 Cells , 2014, Molecules and cells.

[5]  R. Rosell,et al.  Predicting resistance by selection of signaling pathways. , 2014, Translational lung cancer research.

[6]  P. Krawczyk,et al.  Polymorphisms in TS, MTHFR and ERCC1 genes as predictive markers in first-line platinum and pemetrexed therapy in NSCLC patients , 2014, Journal of Cancer Research and Clinical Oncology.

[7]  Leping Li,et al.  Progress of cancer research on astrocyte elevated gene-1/Metadherin (Review) , 2014, Oncology letters.

[8]  B. Zhu,et al.  Knockdown of astrocyte elevated gene-1 (AEG-1) in cervical cancer cells decreases their invasiveness, epithelial to mesenchymal transition, and chemoresistance , 2014, Cell cycle.

[9]  Haiquan Chen,et al.  The pemetrexed-containing treatments in the non-small cell lung cancer, is -/low thymidylate synthase expression better than +/high thymidylate synthase expression: a meta-analysis , 2014, BMC Cancer.

[10]  Yu Liu,et al.  Expression of thymidylate synthase predicts clinical outcomes of pemetrexed-containing chemotherapy for non-small-cell lung cancer: a systemic review and meta-analysis , 2013, Cancer Chemotherapy and Pharmacology.

[11]  Ting Wang,et al.  Association between TYMS Expression and Efficacy of Pemetrexed–Based Chemotherapy in Advanced Non-Small Cell Lung Cancer: A Meta-Analysis , 2013, PloS one.

[12]  C. Gridelli,et al.  PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  Eun Joo Lee,et al.  Thymidylate synthase and ERCC1 as predictive markers in patients with pulmonary adenocarcinoma treated with pemetrexed and cisplatin. , 2013, Lung cancer.

[14]  Tuan S. Nguyen,et al.  Thymidylate Synthase Expression and Outcome of Patients Receiving Pemetrexed for Advanced Nonsquamous Non–Small-Cell Lung Cancer in a Prospective Blinded Assessment Phase II Clinical Trial , 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[15]  A. Buqué,et al.  Thymidylate Synthase Expression Determines Pemetrexed Targets and Resistance Development in Tumour Cells , 2013, PloS one.

[16]  T. Oguri,et al.  Thymidylate synthase gene copy number as a predictive marker for response to pemetrexed treatment of lung adenocarcinoma. , 2013, Anticancer Research.

[17]  J. Sculier Nonsmall cell lung cancer , 2013, European Respiratory Review.

[18]  Minwen Ha,et al.  Association of thymidylate synthase gene 3'-untranslated region polymorphism with sensitivity of non-small cell lung cancer to pemetrexed treatment: TS gene polymorphism and pemetrexed sensitivity in NSCLC , 2013, Journal of Biomedical Science.

[19]  Lian-tang Wang,et al.  AEG-1 expression characteristics in human non-small cell lung cancer and its relationship with apoptosis , 2013, Medical Oncology.

[20]  F. Hirsch,et al.  Significance of Folate Receptor Alpha and Thymidylate Synthase Protein Expression in Patients with Non–Small-Cell Lung Cancer Treated with Pemetrexed , 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[21]  J. Luketich,et al.  The Platinum-Based Treatments for Advanced Non-small Cell Lung Cancer: Is Excision Repair Cross-Complementation Group 1 Low/Negative Expression Better Than Its High/Positive Expression? A Metaanalysis , 2010 .

[22]  M. Fukuoka,et al.  Identification of thymidylate synthase as a potential therapeutic target for lung cancer , 2010, British Journal of Cancer.

[23]  P. Fisher,et al.  Molecular mechanism of chemoresistance by astrocyte elevated gene-1. , 2010, Cancer research.

[24]  Thomas J. Smith,et al.  美国临床肿瘤学会Ⅳ期非小细胞肺癌化疗的临床实践指南更新 , 2010, Zhongguo fei ai za zhi = Chinese journal of lung cancer.

[25]  Libing Song,et al.  Over‐expression of AEG‐1 significantly associates with tumour aggressiveness and poor prognosis in human non‐small cell lung cancer , 2009, The Journal of pathology.

[26]  K. Krejcy,et al.  Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study , 2009, The Lancet.

[27]  Yibin Kang,et al.  The Multifaceted Role of MTDH/AEG-1 in Cancer Progression , 2009, Clinical Cancer Research.

[28]  Talitha L Forcier,et al.  Identification of genes conferring resistance to 5-fluorouracil , 2009, Proceedings of the National Academy of Sciences.

[29]  Xianrang Song,et al.  Knockdown of astrocyte elevated gene-1 inhibits proliferation and enhancing chemo-sensitivity to cisplatin or doxorubicin in neuroblastoma cells , 2009, Journal of experimental & clinical cancer research : CR.

[30]  Michael Reiss,et al.  MTDH activation by 8q22 genomic gain promotes chemoresistance and metastasis of poor-prognosis breast cancer. , 2009, Cancer cell.

[31]  Johan Vansteenkiste,et al.  Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  Dong-Chul Kang,et al.  Astrocyte elevated gene-1: recent insights into a novel gene involved in tumor progression, metastasis and neurodegeneration. , 2007, Pharmacology & therapeutics.

[33]  P. Fisher,et al.  Astrocyte elevated gene-1 (AEG-1) is a target gene of oncogenic Ha-ras requiring phosphatidylinositol 3-kinase and c-Myc , 2006, Proceedings of the National Academy of Sciences.

[34]  G. Scagliotti,et al.  Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase , 2006, Cancer.

[35]  Miklos Pless,et al.  Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  R M Schultz,et al.  LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes. , 1997, Cancer research.

[37]  A. Jemal,et al.  Cancer statistics, 2016 , 2016, CA: a cancer journal for clinicians.

[38]  S. Temin,et al.  Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. , 2016, Journal of oncology practice / American Society of Clinical Oncology.

[39]  S. Temin,et al.  Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. , 2016, Journal of oncology practice.

[40]  K. Thiel,et al.  Drug resistance mediated by AEG-1/MTDH/LYRIC. , 2013, Advances in cancer research.

[41]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.

[42]  N. Dubrawsky Cancer statistics , 1989, CA: a cancer journal for clinicians.